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Poster Session II S3115x104 CD3 cells/kg, no additional GvHD prophylaxis was adminis-
tered. The median age at transplant was 9.9 years (range, 2.9 to 21.6)
and median follow-up 44 months post SCT (range, 13 to 102). Me-
dian CD34+ cell dose infused was 1.14x107/kg (range, 0.49-
6.83x107/kg) and median CD3+ T-cell dose was 3.08x104/kg (range,
1.8x104-1.6x105/kg). The rate of donor engraftment was 82.4% – 3
patients failed to achieve initial donor engraftment but did so after
receiving subsequent haploidentical SCT. Eleven of 17 (65%) pa-
tients received additional T-cell therapies post SCT (donor lympho-
cytes for mixed chimerism, cytotoxic T-lymphocyte therapy or
planned T-cell addback strategies to re-establish T-cell immune re-
constitution) and 2 received additional CD34+ cells for poor graft
function. Two-year disease-free survival for these children is
60.5%. Of the 5 children who died, 2 died of relapse and 3 of treat-
ment-related causes, primarily infection. One patient with p53 mu-
tation developed secondary MDS 2 years post SCT and is alive
with disease. In conclusion, while this data is preliminary, haploi-
dentical transplants using in vivoT-cell depletion with alemtuzumab
and ex vivo T-cell depletion with CD34+ selection offers promising
clinical results in children with ALL in CR1 or CR2.With the addi-
tion of new clinical immunotherapy trials post SCT, we hope to
achieve even higher survival with decreased relapse and deaths
related to viral infection.433
LEUKEMIA RELAPSE: DETECTED BY BONE MARROW CHIMERISM ANAL-
YSIS BUT MISSED BY PERIPHERAL BLOOD ENGRAFTMENT MONITORING
ALONE
Chen, J.1, Chang, C.-C.1,2, Land, G.1,2 1The Methodist Hospital,
Houston, TX; 2Weill Cornell Medical College, Houston, TX
Chimerism analysis is frequently used for the surveillance of en-
graftment especially post allogenic stem cell transplantation for ma-
lignant hematopoietic diseases (HSCT). The most common
method, PCR-based short tandem repeats (STR) analysis, offers
high sensitivity and specificity in monitoring graft chimerism after
HSCT. Multiple panels of STRs have been developed for use on
bone marrow aspirate (BMA) and peripheral blood (PB). In accor-
dance with 2001workshop (tandemmeeting ASBMT) recommenda-
tions, PB has been widely used to serially characterize the
hematologic course of engraftment and/or occurrence. In the pres-
ent study, we evaluated the value of STR assay for surveillance of
acute leukemia relapse in patients with established HSCT engraft-
ments. A total of 87HSCT recipients with clinically stable and estab-
lished engraftment were retrospectively analyzed. All cases had been
monitored by serial STR analysis using both BMA and PB samples
with a commercially available panel of ten markers (D3S1358-
vWA-FGA-AMEL-D8S1179-D21S11-D18S51-D5S818-D13S317-
D7S820). Additionally, patients’ bone marrow biopsies were also
reviewed at the time of BMA STR analysis. Among these 87 patients,
70 patients sustained complete remission and their PB and BMA
showed 100% donor origin in the STR assays. There were 17 pa-
tients who had relapse ranging from 81 days to 442 days after trans-
plantation, as documented by BM biopsy and/or clinical
presentation. All of these 17 patients showed a mixed chimerism
on BMA STR assay at the same time BM biopsy showed relapse.
In these relapse patients, the percentage of donor origin were lower
in granulocytes than in mononuclear cells (52.468% vs 84.564%; p
\ 0.05) while 3 patients showed mixed chimerism in the mononu-
clear cells only. In contrast, there were 4 out of the 17 patients
with negative PB STR assays in the immediate time period around
which the BMA STR analysis became positive. Interestingly, in
one patient when BM STR assay showed mixed chimerism, the
BM biopsy obtained at the same time was inconclusive for relapse.
Our findings indicated that caution should be taken when using
PB STR solely to monitor leukemia relapse because it maymiss early
recurrence. This may delay a change in treatment. Second, BM STR
assay is a very sensitive method in HSCT surveillance even in pa-
tients with a negative or inconclusive BM biopsy. At last, mononu-
clear cells are more sensitive in detecting mixed chimerism than
granulocytes.434
FACILE DOUBLE CORD TRANSPLANT SCREENING AND MONITORING
Bost, D.A., McLaughlin, I.J., Beckert, S. Celera, Alameda, CA
STR-PCR is limited in its utility for screening and monitoring of
donors and recipients in double cord transplants, given its inherent
lack of sensitivity and the presence of stutter artifacts which obscure
potentially informative alleles. If markers are identified for each in-
dividual in a double cord transplant, the manual execution of the al-
gorithm for quantification of individuals is quite time-consuming.
To simplify these analyses, we designed a multiplexed system of
RUO assays and software enabling instantaneous marker identifica-
tion and quantification post-PCR.
We employ a panel of 34 quantitative PCR research assays to bi-
allelic indels in which the probability of finding at least one informa-
tive marker is. 99.9% in unrelated individuals (Caucasian, African,
Japanese, Amerindian populations). The probability of finding at
least one informative marker in siblings is . 99%, 98%, 98% and
97% for European Caucasian, Japanese, Amerindian and African
populations, respectively.
Results: Each research assay was tested using simulated DNA mix-
tures at 0.05%, 0.1%, 0.2% and 0.4% minor component for 250 ng
of input genomic DNA. Each assay detected the 0.05% minor com-
ponent mixture. The limitation at this low sensitivity is input copy
number. In addition, each of the assays in the panel was able to de-
tect, with statistical significance (p\ 0.05), the 2-fold change be-
tween the 0.1% and 0.2% minor component mixtures. Multiple
assays tested on the same mixtures gave highly reproducible results.
We also developed research use software allowing for facile analysis
of marker screening and post-transplant monitoring quantification.
Results are generated with one click of a mouse button.
Conclusions: Use of this research qPCR system for screening and
engraftment monitoring of double cord transplants would enable
rapid identification of informative markers and several logs increase
in sensitivity over the current standard practices. The ability to de-
tect early changes in increasing mixed chimerism, with greater accu-
racy and precision, allows for more effective research into the
potential benefits of earlier detection of clinically significant events,
such as relapse or rejection.435
ATTEMPTS TO OPTIMIZING THE OUTCOMES OF ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION IN OLDER PATIENTS ($60 YEARS)
WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME
Hu, J.1, Sykes, J.2, Panzarella, T.2, Sharma, A.1, Kuruvilla, J.1,
Lipton, J.H.1, Wright, J.1, Messner, H.1, Gupta, V.1 1Princess Margaret
Hospital, Toronto, ON, Canada; 2Princess Margaret Hospital, Toronto,
ON, Canada
Using a non-myeloablative (NMA) regimen [Fludarabine 125mg/
m2 and total body irradiation (TBI) 200cGY], we previously reported
the feasibility of allogeneic hematopoietic cell transplantation
(HCT) in older patients (n 5 24) with AML/MDS using matched
sibling donors (MSD) (Gupta et al, 2005, BBMT). GvHD prophy-
laxis was with Cyclosporine (CsA) (42 days) and Mycophenolate
(MMF) for (30 days); CsA was tapered at 42 days in the absence of
GvHD.While survival was reasonable; 2 main issues were identified:
early relapse and severe chronic GvHD in some patients. To address
these issues, we added IV Busulphan (3.2mg/KBWIV daily x 2 days)
to Flu/TBI regimen, and increased the duration of GvHD prophy-
laxis with CsA from 42 days to 100 days. We compare the outcomes
of these 2 sequential strategies: Cohort 1 (n 5 24, treated 2000-
2004), less intense NMA regimen and shorter GvHD prophylaxis;
Cohort 2 (n 5 31, treated 2005-2009), more intense NMA regimen
and longer GvHD prophylaxis. The median age of all study patients
(n5 55) was 63 years (range 60-71); 47 (86%) had AML in CR1 (n5
33) or CR2 (n5 14), and 8 (14%) hadMDS; 22% had severe comor-
bidities; and 29% had adverse risk cytogenetics. Baseline character-
istics were well-matched in the two cohorts, except cohort 2 had 6
(19%) patients with unrelated donors HCT. Median follow-up of
survivors in cohort 1 and 2 was 72 months (13-102) and 31 months
(16-49), respectively. A significantly higher proportion of patients
had grade $ 2 stomatitis (Bearman Criteria) in the later cohort
S312 Poster Session II(35% vs. 0, p 5 0.001). Neutrophil and platelet recovery was longer
in the later cohort, although not statistically significant. Cohort 2
had earlier onset for acute GvHD (64 vs. 49 days, p 5 0.048), but
late onset for chronic GvHD (202 vs. 122 days, p5 0.001). Although
cumulative incidence (CI) of grade II-IV acute GvHDwas similar in
two cohorts (cohort 1, 62% vs. cohort 2, 53%), there was trend to-
wards decreased grade III-IV acute GvHD (34 vs.16%, p 5 0.26)
and chronic GvHD (71% vs. 60%, p 5 0.08) in cohort 2. At 2-
year, CI of relapse, non-relapse mortality, leukemia-free and overall
survival were 30%, 30%, 40% and 46%, respectively for all study pa-
tients, and no significant differences noted in cohort 1 and 2 for these
outcomes. Although a trend towards decreased severe acute GvHD
and chronic GvHD is encouraging in the later cohort in this study,
more effective novel strategies are required for prevention of
GvHD, an issue of major concern in older patients.436
IMMEDIATE ADVERSE EVENTS FOLLOWING INFUSION OF EX VIVO-EX-
PANDED CORD BLOOD FOR STEM CELL TRANSPLANTATION
Bear, A.S.1, Hanley, P.J.1, Bosque, D.M.2, de Lima, M.J.2, Kebriaei, P.2,
Hosing, C.2, Heslop, H.E.1, Bollard, C.M.1 1Baylor College of Medicine,
Texas Children’s Hospital, The Methodist Hospital, Houston, TX; 2The
University of Texas MD Anderson Cancer Center, Houston, TX
Umbilical cord blood (CB) is utilized with increasing frequency to
restore hematopoiesis in bone marrow transplant patients lacking
a suitableHLA-matched donor. CB transplantation (CBT) is limited
by low cell doses and delays in neutrophil and platelet engraftment.
CB progenitors expanded ex vivo prior to transplantation provide
more rapid hematopoietic and immune reconstitution, as well as
less engraftment failure compared to unmanipulated CB. However,
the relative safety regarding the infusion of ex vivo-expanded CB has
not been systematically examined. Here we review the immediate ad-
verse events (AE) associated with infusion of ex vivo-expanded CB
occurring within 24 hours of infusion in 92 patients enrolled in
two clinical CB expansion trials at the MD Anderson Cancer Center
from February 2004 to May 2010. The median age of enrolled pa-
tients was 42 years (range 3-66), with a predominance of males (n
5 60). 47 patients received a CBT for treatment of acute leukemia.
24 patients had a previous stem cell transplant (22 autologous and
2 allogeneic). The majority of patients (n 5 80) were pre-medicated
prior to transplantation with a combination of diphenhydramine and
steroids. All patients received an unmanipulated CB unit followed by
infusion of the ex vivo-expanded CB product after 1 hour. ABOmis-
matching was observed in 28/89 and 22/89 unmanipulated and ex
vivo-expanded CB products, respectively. The mean volume of the
infusions was 109 mls (range 45-249 mls) for the unmanipulated
CB units and 134 mls (range 39-180 mls) for the expanded product.
A total of twoGrade 1-2 and fiveGrade 3-4 infusion reactions occur-
ring within 24 hours after CBTof both products were observed.This
resulted in an AE rate of 8%. The majority of the AEs manifested as
signs of dyspnea and hypoxia and could be attributed to either vaso-
vagal reactions or volume overload. However, no association with
patient age, disease, previous transplant, total infusion volume, or
ABO incompatibility was observed. In summary, infusion related
toxicities in patients who receive an unmanipulated and ex vivo-ex-
panded double CBT appears relatively low. We conclude that infu-
sion of unmanipulated followed by expanded CB products is a safe
procedure associated with a low probability of inducing severe reac-
tions. We are currently examining the incidence of infusion related
toxicities in patients who have received only unmanipulated CB
products.
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PROSPECTIVE TRIAL OF PRE-TRANSPLANT 5-AZACITIDINE ON HEMATO-
POIETIC CELL TRANSPLANTATION OUTCOMES FOR MYELODYSPLASTIC
SYNDROME AND CMML
Field, T.L.1, Perkins, J.1, Pidala, J.1, Nishihori, T.1, Tomblyn, M.1,
Fernandez, H.1, Perez, L.1, Karfan-Dabaja, M.A.1, Komrokji, R.2,
Lancet, J.2, Ayala, E.1, Alsina, M.1, Ochoa, L.1, Kim, J.3, List, A.2,
Anasetti, C.1 1H. Lee Moffitt Cancer Center and Research Institute,
Tampa, FL; 2H. Lee Moffitt Cancer Center and Research Institute,Tampa, FL; 3H. Lee Moffitt Cancer Center and Research Institute,
Tampa, FL
We report the results of a prospective observational clinical trial
with the objective of evaluating HCT outcomes following pre-
HCT therapy with 5-azacitidine. Twenty-three patients seen in
consultation for HCT and medically eligible for a donor search
were enrolled and received 5-azacitidine [75mg/m2 for 7 days every
4 weeks] until a suitable donor was identified. Four did not proceed
to transplant for the following reasons: failure to obtain insurance
approval due to patient age, failure of the pre-HCTorgan evaluation
although a donor was identified, CNS hemorrhage in setting of
chronic anti-coagulation five days prior to HCT admission and
one (62 years) declined HCT as only a HLA-A mismatched donor
was available.Nineteen patients received aHCT following amyeloa-
blative targeted busulfan fludarabine regimen. Median age at HCT
was 57 years (25 – 67). IPSS at diagnosis was Int-1 (2), Int2 (9) and
high (5), CMML1 (1), AMLM6 (1) and not evaluable (NE) (1). Cy-
togenetic risk was good (7), intermediate (5) and poor (7). Three pa-
tients had therapy relatedMDS. Patients received amedian of 4 (1-6)
cycles of 5-azacitidine. Median time from diagnosis (or time of pro-
gression and start of therapy in 2 patients) to HCT infusion was 195
days (107 – 350). Response to 5-azacitidine prior to HCT by the In-
ternational Working Group 2006 criteria included partial response
(8), stable disease (9) and 2 progressed. Two received leukemic in-
duction chemotherapy prior to HCT. IPSS score prior to HCT
was Low (1) Int-1 (6), Int2 (9) and poor (1) and CMML1 (2). Source
of donor cells was peripheral blood siblings (7), matched unrelated
donors (10) and mismatch unrelated donors (2). Median follow-up
from HCT is 440 days (83-696). There are 3 patients who did not
achieve remission (1) or relapsed (2) and 1 of the three remains alive
with active disease. There are 3 non-relapse deaths, 2 due to infection
and 1 due to GVHD. All deaths occurred between days 180 – 262. At
one year OS is 69% (SE 0.12) and DFS is 63% (SE 0.12). In conclu-
sion, pre-HCT 5-azacitidine was well tolerated, provided control of
disease as a bridge toHCT and did not impose additional toxicity af-
ter allogeneic HCT with a promising 1 year progression-free
survival. Controlled trials are needed to determine whether post-
transplant relapse and survival are improved by pre-transplant 5-aza-
citidine.
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FASTER REGISTRATION ON INTERNATIONAL DONOR REGISTRIES AND
SHORTER TIME TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION AFTER HAVING FOUND A DONOR CONFERS BETTER OUT-
COME IN ACUTE LEUKEMIA PATIENTS
Michallet, M.1, Sobh, M.1, Morisset, S.1, Thomas, X.1, Chelghoum, Y.1,
Labussiere, H.1, Nicolini, F.1, Ducastelle, S.1, Barraco, F.1, Tedone, N.1,
Fatoum, J.1, Detrait, M.1, Rey, S.2, Dubois, V.2 1Hematology, Hopital
Edouard Herriot, Lyon, France; 2Etablissement Francais du Sang, Lyon,
France
A patient has 30% chance to find an HLA identical sibling donor
(SD) and 40% chance to find a suitable unrelated donor (UD), 40%
of registered patients on international registries relapse or die before
finding a donor. We evaluated the outcome in acute leukemia (AL)
patients, whether they had anHLA identical SD, an UD or no donor
(ND) after registration on France Greffe de Moelle (FGM) registry,
either transplanted later or not. Secondary objectives were to evalu-
ate the impact of intervals diagnosis-allo-HSCT, donor finding-allo-
HSCT, registration-allo-HSCT, on OS and EFS. We analyzed 251
AL patients, 117 (47%) males and 134 females, median age at diag-
nosis 40 years [16-66], 177 (71%) AML and 75 ALL. Seventy six
(30%) patients had an available SD and received allo-HSCT within
a median time of 3.5 months (0.5–43) and 38 (15%) had SD but were
not transplanted due to early relapse and/or death. For patients with
no available SD, a registration on FGM registry was done, 137 pa-
tients were registered after a median interval of 2.3 months (0.4-
135) from diagnosis, 33 (13%) patients did not find any donor and
they received the standard of care; 104 (41%) patients found an
UD or UCB unit after a median time of 1.6 months (0.3-26): 86
with UD of which only 60 have been transplanted within a median
time of 2.3 months (0.4–14), 18 with UCB of which only 17 were
transplanted. Among transplanted patients, 113 (74%) were in CR,
40 in\ CR. Fifty (33%) received PBSC, 86 (57%) received BM
and 17 (10%) UCB units. For conditioning, 56 (37%) were RIC
